PMID- 35836834
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Impact of Helicobacter pylori Infection and Outcome of Anti-Helicobacter pylori 
      Therapy in Patients with Reflux Laryngopharyngitis.
PG  - 8266321
LID - 10.1155/2022/8266321 [doi]
LID - 8266321
AB  - OBJECTIVES: This study was designed to explore the relationship between 
      Helicobacter pylori (Hp) infection and reflux laryngopharyngitis (RLP) and to 
      evaluate the outcome of anti-Hp therapy in improving RLP symptoms. METHODS: A 
      total of 410 patients with RLP were enrolled and tested for Hp infection. The 
      association of Hp infection with reflux symptom index (RSI) and reflux finding 
      score (RFS) was determined. Hp-positive patients received either a proton pump 
      inhibitor (PPI) omeprazole alone (control group) or a combination regimen 
      (experimental group) consisting of omeprazole, mosapride citrate, amoxicillin, 
      and clarithromycin. Therapeutic outcomes were compared 4 weeks later. RESULTS: Of 
      the 410 participants, 290 were Hp-positive and 120 Hp-negative. Both RSI and RFS 
      were significantly higher in Hp-positive patients than in Hp-negative patients. 
      Hp infection status was positively correlated with RSI (P < 0.05) and RFS (P < 
      0.05). The overall response rate was higher in the experimental group than in the 
      control group. Both the groups had a significant reduction in RSI and RFS after 
      therapy, with a greater improvement in the experimental group (P < 0.05). 
      CONCLUSION: Our findings establish a link between Hp infection and RLP. Anti-Hp 
      therapy improves RSI and RFS in RLP patients. Therefore, Hp eradication drugs may 
      be added to the PPI-based regimen in the treatment of RLP.
CI  - Copyright (c) 2022 Huili Shen et al.
FAU - Shen, Huili
AU  - Shen H
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
AD  - Department of Otolaryngology-Head and Neck Surgery, The Fourth People's Hospital 
      of Shaanxi Province, Xi'an, China.
FAU - Chen, Yijie
AU  - Chen Y
AD  - College of Medicine, Xi'an Jiaotong University, Xi'an, China.
FAU - Li, Xiaohui
AU  - Li X
AD  - College of Medicine, Xi'an Jiaotong University, Xi'an, China.
FAU - Yan, Jing
AU  - Yan J
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Zhao, Junjie
AU  - Zhao J
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Kong, Demin
AU  - Kong D
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Shi, Yanxia
AU  - Shi Y
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Li, Zhihui
AU  - Li Z
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Wang, Jihong
AU  - Wang J
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Shao, Na
AU  - Shao N
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
FAU - Wang, Zhenghui
AU  - Wang Z
AUID- ORCID: 0000-0001-5766-2089
AD  - Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated 
      Hospital of Xi'an Jiaotong University, Xi'an, China.
LA  - eng
PT  - Journal Article
DEP - 20220705
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9276480
COIS- The authors declare that there are no conflicts of interest related to this 
      study.
EDAT- 2022/07/16 06:00
MHDA- 2022/07/16 06:01
PMCR- 2022/07/05
CRDT- 2022/07/15 02:30
PHST- 2022/04/14 00:00 [received]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/07/15 02:30 [entrez]
PHST- 2022/07/16 06:00 [pubmed]
PHST- 2022/07/16 06:01 [medline]
PHST- 2022/07/05 00:00 [pmc-release]
AID - 10.1155/2022/8266321 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jul 5;2022:8266321. doi: 
      10.1155/2022/8266321. eCollection 2022.